Jazz Pharmaceuticals

Photo
10.02.2021 • News

Jazz Buys the UK’s GW Pharma

Ireland-based multinational drug company Jazz Pharmaceuticals is to buy UK biopharma GW Pharma for $7.2 billion, creating a leader in neuroscience. The boards of directors of both companies have unanimously approved the deal, which is expected to close in the second quarter, subject to customary conditions and regulatory approvals.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.